(Q42175070)

18 October 2017

EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study (English)

1 reference

18 October 2017

1 reference

1 reference

Christopher Dunham

2

0 references

Uri Tabori

3

object named as

Uri Tabori

1 reference

18 October 2017

10

Nada Jabado

0 references

Lucie Lafay-Cousin

7

object named as

Lucie Lafay-Cousin

1 reference

18 October 2017

17

Cynthia Hawkins

1 reference

18 October 2017

Amanda M Li

1

1 reference

18 October 2017

Anne-Sophie Carret

4

1 reference

18 October 2017

P Daniel McNeely

5

1 reference

18 October 2017

Donna Johnston

6

1 reference

18 October 2017

Beverly Wilson

8

1 reference

18 October 2017

David D Eisenstat

9

1 reference

18 October 2017

Shayna Zelcer

11

1 reference

18 October 2017

Mariana Silva

12

1 reference

18 October 2017

Katrin Scheinemann

13

1 reference

18 October 2017

Christopher Fryer

14

1 reference

18 October 2017

Glenda Hendson

15

1 reference

18 October 2017

Abbas Fotovati

16

1 reference

18 October 2017

Stephen Yip

18

1 reference

18 October 2017

Sandra E Dunn

19

1 reference

18 October 2017

Juliette Hukin

20

1 reference

18 October 2017

language of work or name

English

0 references

publication date

13 January 2015

1 reference

18 October 2017

1 reference

18 October 2017

121

1 reference

18 October 2017

1499-1507

1 reference

18 October 2017

9

1 reference

Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.

18 October 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Postoperative radiation therapy for grade II and III intracranial ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Intracranial ependymomas of childhood: long-term outcome and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

The genetic and epigenetic basis of ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

A prognostic gene expression signature in infratentorial ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Molecular staging of intracranial ependymoma in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

CDKN2A/p16 in ependymomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Correlation of p53 and KI-67 expression with grade and subtype of ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

EZH2 is essential for glioblastoma cancer stem cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Cross-species genomics matches driver mutations and cell compartments to model ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

inferred from DOI database lookup

7 January 2021

based on heuristic

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29198

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.29198

1 reference

18 October 2017

1 reference